ViroCell Biologics is a Contract Development and Manufacturing Organization (CDMO) specializing in the design, optimization, and GMP manufacturing of lentiviral and retroviral vectors. The company focuses on de-risking early-stage development by engineering complex viral vectors with specific performance and safety attributes. This expertise enables the acceleration of novel cell and gene therapies toward clinical trial readiness.
Funding
$164.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
FLFounders
Product
Problem
The development of novel cell and gene therapies is often hindered by the limited availability of high-quality viral vectors manufactured under GMP conditions. Existing solutions may lack the necessary expertise in vector design, optimization, and early-stage de-risking, leading to delays and increased costs in bringing therapies to clinical trials.
Solution
ViroCell Biologics is a contract development and manufacturing organization (CDMO) specializing in the design, optimization, and GMP manufacturing of lentiviral and retroviral vectors. The company accelerates the development of cell and gene therapies by offering services from vector design and de-risking to GMP vector manufacturing for clinical trials. ViroCell leverages its team's extensive experience in vector development to engineer complex viral vectors with enhanced performance, safety attributes, and improved yields.
Target Audience
ViroCell Biologics serves biotechnology and pharmaceutical companies developing novel cell and gene therapies, requiring lentiviral and retroviral vectors for clinical trials.
Features
- Vector design and optimization services, including a MicroBatch© process for rapid identification of high-titer viral vector designs
- Development of engineered lentiviral and retroviral vector backbones for improved safety and efficacy
- GMP manufacturing using both adherent and suspension cell lines at scales from 12L to 50L
- Process development services to maximize upstream and downstream process yields
- Qualified Quality Control (QC) release testing vendors to deliver turnaround times of less than 14 weeks
- Support for regulatory submissions to MHRA, FDA, and EMA